 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Biological NanoParticle (BNP™) and Self-Complementary Vector TechnologiesBNP™ delivery technology allows selective and highly efficient and safe therapeutic protein expression in the heart. BNPs™ are synthetically derived from components of different serotypes of adeno-associated viruses (AAV), as well as other parvoviruses. These nano-sized particles have been selected and engineered specifically for their biological propensities for targeting and transducing heart muscle tissue, as well as being immune evasive and pathogenically safe. Once administered to the patient, BNPs™ transport nucleic acids to heart muscle cells and then deliver them to the nucleus, where they code for a desired therapeutic protein. Historically, there has been varying delivery vehicles used to deliver therapeutic genes. Use of viruses, called viral vectors, takes advantage of a virus' natural ability to introduce DNA to cells. Several different recombinant viral vectors have been harnessed for the delivery of genes, including adenovirus, herpes simplex virus, lentivirus, and adeno-associated virus. However, due to its non-pathogenic properties, avoidance of an immune response to vector transgene, ability to maintain efficient and long-term expression, and ease of genetic manipulation, recombinant adeno-associated virus (rAAV) has quickly become the gene-delivery vector of choice for a multitude of targets. The effectiveness of BNP™’s ability to efficiently deliver a transgene is enhanced by the Self-Complementary Vector Technology which acts as a booster to the BNP™ to reduce the amount of virus required for transgene delivery, thereby reducing the likelihood of an immune response and a toxic result. |
||||
| NanoCor Products | ||||
|
|
||||
| Contact Us | ||||
|
||||
870 Martin Luther King Jr. Blvd.
NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a minimal-invasive treatment for these patients and advance the current standard of care.